A small and powerful wearable device ergonomically designed to address the critical need for complete and continuous respiratory monitoring.
Hospitals Deal with a High Rate of Respiratory Compromise due to the use of Opioids for Pain Management
Respiratory Depression occurs in up to 46% of patients receiving opioids on the hospital general care floor.
It is one of the top five conditions leading to increased hospital costs in the United States.
Hospitals Need Better Monitoring of Patients Taking Opioids
The Joint Commission, the Anesthesia Patient Safety Foundation and 15 additional medical associations recommend continuous monitoring of patients on opioids.
Use of monitoring equipment is limited
Expensive – only few patients are continuously monitored.
Patients must be stationary and wear a mask or canula.
Intermittent monitoring is insufficient
33% of spot checks are not done on time and 25% are incomplete.
Only 40% of patients are monitored as ordered by physician.
Respiratory Depression is Costly
350,000 respiratory arrests occur each year.
$5M added hospital days $12B additional costs $4500/episode
RTMsense is a breakthrough respiratory monitoring technology, harnessing the power of AI and human-centric design to revolutionize patient care.
RTM Vital Signs, LLC (RTM) is a medical device company engaged in the transformation of healthcare from reactive to proactive, preventive, and person-centered through real-time, continuous, cost-effective monitoring and analyzing critical health information in both hospital and ambulatory patients with the greatest healthcare needs: respiratory and cardiac care.
RTM monitors also have applications in fitness, industrial safety and veterinary medicine
